PREDNISOLONE METAZOATE

Prednisolone metazoate is a modified ester designed to provide prolonged glucocorticoid action. It suppresses immune responses and inflammation. Side effects include edema, mood disturbances, glucose intolerance, muscle weakness, and increased risk of infections and adrenal insufficiency. Only GMP materials will be supplied, logistics all according to GDP.

SKU: f7fb6360d36d Category: Tag:

Product Description


Mechanism of Action

PREDNISOLONE METAZOATE exhibits a complex, multipathway biochemical activity profile influencing enzymatic cascades, receptormediated signalling networks, mitochondrial respiration, oxidativestress balance, intracellular ion regulation, membranepotential stability and transcriptionfactor activation. Its structural framework suggests potential interactions with catalytic residues, allosteric regulatory pockets, membraneembedded receptor complexes and intracellular signalling scaffolds. These interactions may modulate phosphorylation patterns, secondmessenger systems (Ca²⁺, IP, DAG, cAMP), ATP turnover, ROS equilibrium, cytoskeletal organisation and organelle stressresponse thresholds.

Depending on dosing, PREDNISOLONE METAZOATE can influence metabolic flux routing, alter chromatin accessibility, modify vesicular transport, reshape mitochondrial output and regulate transcriptional clusters associated with cellular survival, apoptosis, autophagy, inflammatory signalling and metabolic adaptation. This multiaxis behaviour supports its wide applicability in advanced biochemical and pharmacodynamic research systems.

Benefits and Advantages

The compound is widely utilised for:

  • Receptorligand interaction analysis and affinity modelling
  • Enzymekinetic profiling and catalyticpathway reconstruction
  • Mitochondrialbioenergetics assays and oxidativestress evaluation
  • Multiomics integration (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membranedynamics studies
  • Apoptosis, necroptosis, autophagy and ferroptosis pathway characterisation
  • SAR (structureactivity relationship) development and molecular screening
  • Pharmacodynamic modelling and mechanistic doseresponse simulations

Side Effects and Risks

Potential laboratoryobserved risks include:

  • Excessive ROS production and oxidative imbalance
  • Mitochondrial hyperactivation or suppression of electrontransport complexes
  • Ionchannel dysregulation (Na⁺, K⁺, Ca²⁺)
  • Unintended receptor crosstalk or inhibition
  • Cytoskeletal destabilisation and membrane-integrity compromise
  • Dosedependent cytotoxicity or activation of apoptotic/autophagic pathways
  • Transcriptional or epigenetic instability
  • Upregulation of inflammatory cascades (NF-κB, JNK, p38 MAPK)

Use exclusively within controlled laboratory conditions and according to strict biosafety standards.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C27H33FO8

Molecular Weight

504.55 g/mol

CAS Number

2624-88-8

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

IUPAC/Chemical Name

(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(2-methylsuccinic acid) ester

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download